weakness, alterations in taste perception, leucopenia, thrombocytopenia, and infection [1] .
In cancer management, early diagnosis and start of cancer treatment are warranted. There are several drugs discovered and available for the treatment of different cancer types, however some drugs are preferred to use as monotherapy and some are used along with other agents as combination therapy. Some drugs are given orally and some are given by the intravenous (iv) route. Example for drugs that are given as a single iv injection are cisplatin, dacarbazine, carmustine, mechlorethamine, streptozotocin, oxaliplatin, cytarabine, carboplatin, ifosfamide, doxorubicin, daunorubicin, docetaxel, paclitaxel, mitoxantrone, etoposide, topotecan, 5-fluorouracil and methotrexate; and as a single oral dose are procarbazine, hexamethylmelamine cyclophosphamide, vinorelbine, etoposide, capecitabine, and fludarabine [5] [6] [7] .
Chemotherapy-induced nausea and vomiting (CINV) is the most feared common side effect linked with cancer therapy [8] . Nausea is an unlikable wave like symptom occur in the back of the throat and or the epigastria that may wind up in vomiting. Vomiting is a self-limited, short-lived, persuasive expulsion of the contents present in stomach, duodenum and jejunum through oral cavity [9] . More than 80 % patients who receive cancer chemotherapy experience nausea and vomiting (NV). CINV adversely affects patients quality of life (QoL), causes serious metabolic complications, and leads to poor compliance to anticancer regimen [10] .
Frequent
vomiting associated with cancer chemotherapy causes loss of body fluids and electrolyte imbalance. CINV also reduces the tendency to eat or drink anything, and affect physical, emotional and social wellbeing of cancer patients [11] . If this condition continues it might cause fatigue, anxiety, lack of concentration, impairment of wound healing, weight loss, lack of appetite and it would became a serious health problem very quickly [12, 13] .
Several classifications of CINV are widely used including acute, delayed, anticipatory, breakthrough and refractory. Acute CINV starts during the first 24 h, usually within the first few minutes to hours after the administration of chemotherapy. Delayed CINV develops in patients 24 h after the administration of chemotherapy. It may continue up to 6 d and it commonly occurs with cisplatin, carboplatin, cyclophosphamide and anthracyclines. Anticipatory NV starts in patients before receiving chemotherapy due to a prior adverse experience with chemotherapy. Breakthrough CINV occurs despite prophylactic treatment. Refractory NV occur throughout subsequent cycles of chemotherapy when antiemetic prophylaxis is unsuccessful in earlier cycles. The different grading of CINV and the risk category of anticancer drugs are presented in Tables 1 [13] and 2 [14] , respectively.
Based on this risk criterion there are specific strategies available under chemotherapy guidelines. There are several guidelines commonly used nowadays, such as the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology. These guidelines are given in Tables 3 [15] [16] [17] and 4 [18, 19] .
In various hospitals, different antiemetic guidelines are followed and proper utilization of these guidelines in hospitals is evaluated through drug utilization methods. Drug utilization evaluation (DUE) is a potential, ongoing, and systematic tool for the critical evaluation of utilization of drug(s) and to ensure that the medicines are used appropriately and rationally. It can be used to provide early signals of irrational and misuse of drugs, also used to enhance the appropriate use of drugs, improvement in quality control cycle and its continuous quality improvement [20] [21] [22] . DUE can provide adequate insight into the rational use of drugs and can increase the awareness of how drugs are being used to treat various diseases. DUE is most meaningful in continuous evaluation system and when it is followed over a period of time, trends in drug use can be recognised [20] . Researchers can estimate [13] the rational, overuse and misuse of drugs and or alternatives, and the extent of drugs use. It can be used to analyze and compare utilization pattern of drug(s) for the treatment of disease(s) with current guidelines and recommendations. Inconsistent use with reference to guideline recommendations in treating disease NCCN: National Comprehensive Cancer Network, ASCO: American Society of Clinical Oncology might adversely affect patients' QoL and also cause huge economic burden [22] . Hence, this study was aimed to evaluate the antiemetic guidelines consistency and the effectiveness of antiemetics in controlling CINV in cancer chemotherapy patients.
MATERIALS AND METHODS
A study was carried out in chemotherapy patients who had completed their first chemotherapy cycle in the department of haemato-oncology of an 800 bed teaching hospital from September 2016 to August 2018. A total of 1725 patients who received antiemetics along with cancer chemotherapy were included in this study after obtaining their informed consent. Patients receiving both chemo and radiation therapy were excluded from the study.
Study protocol:
The study participants were categorized into 2 groups, the guideline-consistent chemotherapy prophylaxis group (GCCP) and the guideline-inconsistent chemotherapy prophylaxis group (GICP) where patients received antiemetic prophylaxis as per the standard guidelines to control CINV. Further, based on the emetogenicity of chemotherapy regimen given, three groups were created, highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC 
RESULTS AND DISCUSSION
This prospective study was aimed to evaluate antiemetic guidelines consistency and the effectiveness of antiemetics in controlling CINV in cancer chemotherapy patients. A total of 2400 cancer patients were admitted to the hospital for their treatment during the study period. Out of this, 675 patients were receiving both chemo and radiation therapy and were excluded from the study. Out of 1725 patients enrolled in the study, 914 (53 %) were female and 811 (47 %) were male. Sixty percent (n=1035) patients were given the medication according to standard guidelines and 40 % (n=690) were not ( Table 8 .
CINV has a major impact on the daily lives of cancer patients and causes serious harm to the body. The failure of antiemetic therapy will adversely affect the patients QoL. CINV can be prevented or reduced by using appropriate antiemetic therapy. The most important factors that determine the effect of antiemetics in CINV are narrow patient selection, well-defined protocolbased chemotherapy, and suitable antiemetic regimen.
Since 1960s, studies of antiemetics in cancer patients have been a great field of medical research, but CINV is still a major issue in cancer patients. Substantial progress in the understanding of the mechanism of CINV stimulated the researchers to develop new antiemetics such as antidopaminergics, corticosteroids, 5-HT3 receptor antagonists (5-HT3RA), NK1 receptor antagonists and also the new antipsychotic agent olanzapine. Development of these drugs has led to the establishment of numerous international guidelines for the prevention and treatment of CINV [23] .
In this prospective observational study, patients were evaluated after their first chemotherapy cycle to assess the efficacy and outcome of antiemetics to reduce CINV. A total of 1725 patients received anticancer chemotherapy and among them HEC (n=897; 52 %) was given to a majority of patients followed by MEC (n=621; 36 %), and LEC (n=207; 12 %) chemotherapy.
In this study, majority of the participants were female (n=914, 53 %), which is similar to the studies reported by De Tursi et al. [24] and Elizabeth et al. [25] in which female participants were 65 and 79 %, respectively. In the gender wise distribution of cancer, female cancer patients are more due to their lifestyle and food habits, which led to breast and cervical cancer. In this study most of the patients were treated with [26] and Hilarius et al. [27] , where most of the patients were treated with HEC. However this finding is not in agreement with that reported by Baburaj et al. [28] and Aapro et al. [29] , where most of the patients were treated with doxorubicin and cyclophosphamide combination, as cisplatin-induced delayed CINV intensity peaks at 2-3 d and might last for few days after the administration of chemotherapy [30] . HEC was prescribed in higher proportion in GICP group than GCCP while MEC was prescribed in higher proportion in GCCP than GICP group.
In this study, adherence to NCCN, MASCC, and ASCO guidelines were higher with GCCP group when compared to the GICP group even though these guidelines have some differences among them. All guidelines provide clinicians with updated references and a list of recommendations developed based on the international experts opinion on optimum use of antiemetics. This finding is consistent with the studies by Aapro et al. [29] and Gilmore et al. [31] proved that the guideline adherence was higher with GCCP group than GICP patients.
As the chemotherapy and antiemetics were administered using NCCN, MASCC, and ASCO guidelines the number of patients with CINV was less in the GCCP group which evident that only 46 (2.67 %) patients in GCCP had any one type of emesis, whereas 270 (15.65 %) patients in GICP group had either acute, delayed or acute and delayed emesis. Around 82 % (n=1409) have not had any episode of NV during the study period. These findings strengthen the utilization of treatment guidelines for improved QoL of cancer patients. Within the guideline groups there was no significant difference between the types of emesis, which is similar to Bloechl et al. [32] study where there is no difference between delayed and acute NV.
Antiemetics were considered for readministering within one-week period after the patient experience any acute or delayed emesis to control emesis and to find out the failure rate of antiemetic therapy in CINV.
Among those 46 patients in GCCP and 270 patients in GICP groups with acute to acute and delayed emesis, 40 patients in GCCP and 103 patients in GICP group were observed with grade-1 NV and henceforth no antiemetics were readministered again in these patients. However, 167 patients in GICP and six patients in GCCP groups were found to have grade-2 and above NV, hence antiemetics were readministered to control the CINV, which indicate the higher failure rate (10 %) of antiemetics to control CINV. However, no iv fluids were indicated for these patients. The failure rate is more in current study GICP group (9.68 %) compared to other studies where the failure rate is very negligible as the treatment was followed using standard guidelines NCCN, MASCC and ASCO [30, 32] .
Among the 173 patients who fall under the category of failure of therapy, cisplatin at a dose of 70 mg/m 2 , cyclophosphamide 600 mg/m 2 , dacarbazine 100 mg/m 2 and doxorubicin 60 mg/m 2 produced CINV in majority of the patients. This finding is consistent with other studies that the delayed CINV is common in chemotherapy regimens that involved cisplatin, carboplatin, cyclophosphamide, and/or doxorubicin [30, 33, 34] .
The prevalence of guideline consistent CINV prophylaxis was higher, and there were no severe CINV among patients who received antiemetics based on the guidelines when compared to those who did not receive antiemetics based on the guidelines. Similar results were observed in Gilmore et al. [31] study where no CINV was significantly higher in the GCCP than the GICP cohort (53.4 vs. 43.8 %). The study carried out by Aapro [29] also proved that complete response rate was higher in GCCP followers than GICP. Majority of the study participants were prescribed with palonosetron, dexamethasone and aprepitant combination as these drugs are more effective in controlling cisplatin induced NV. In many studies, antiemetics were mostly tested on patients who received cisplatin, a HEC and most HCP agree an agent that inhibit or reduces emesis after cisplatin therapy will be effective for other chemotherapeutic agents with high-to-moderate emetogenicity [33] [34] [35] .
Dexamethasone alone or in combination with 5-HT3RA and/or NK-1 receptor antagonist also recommended to alleviate CINV when patients receiving HEC/ MEC. It is extensively recommended in all guidelines that corticosteroids are the most extensively studied and are widely available. Recent studies recommend dexamethasone for the management of delayed CINV [28, 30, 34, 35] .
NV is the most common and frequently reported serious side effect of almost all anticancer agents and it adversely affect patients' daily functioning and health-related QoL. The introduction of 5HT3RA has a significant advancement in inhibiting CINV. Aprepitant, a drug which was introduced recently that selectively blocks the binding of substance-P at the NK-1 receptor in central nervous system, has been shown to have potential antiemetic activity over 5HT3RA, corticosteroid, dexamethasone, and also inhibit both acute and delayed emesis of HEC.
Clinical practice guidelines for the management of various diseases are being promoted for helping practitioners to take appropriate clinical decisions. In addition, enhance the effectiveness of drugs and reduces the health care costs. This study showed that the treatment for cancer patients was according to the standard guidelines. CINV particularly acute, delayed NV are continuing to be a significant problem for cancer patients with chemotherapy. In this study the guideline consistent group had complete response and control as less NV reported.
In the current study there were 316 patients had CINV and majority were inconsistent to the chemotherapy guidelines. However, the patients who consistent with chemotherapy guidelines have not had any emesis during and after their chemotherapy. This emphasizes the importance of following anticancer chemotherapy guidelines. Further, it proved that the patient consistent to GCCP (NCCN, ASCO and MASCC) received effective antiemetic therapy and therefore no much failure in GCCP group. However, there is 10 % failure rate in GICP group in the current practice of the tertiary care teaching hospital in India. Hence this study accentuates the strict utilization and follow up of anticancer chemotherapy guidelines.
Even though the emetogenicity of anticancer drugs are widely accepted as the most common and important risk factor for CINV, it plays a major role in the appropriate selection of antiemetic therapy. This study findings also provide support for the use of GCCP to reduce the incidence of CINV in HEC, MEC and LEC. Moreover, it also indicated that there is a major benefit of using guideline consistent antiemetic therapy to achieve CINV end points in the acute and delayed phases. Hence, this study strongly encourages the healthcare professionals of the country to adhere with all anticancer chemotherapy guidelines for better health outcomes for patients.
